Dr. Falk Pharma GmbH and Lipid Therapeutics, a biotechnology company focused on novel treatments for inflammatory bowel disease, today announced that they have entered into a licensing agreement for the European rights to Lipid Therapeutics' lead product, LT-02, for ulcerative colitis.

(Schepens Eye Research Institute) Scientists from the Schepens Eye Research Institute, a subsidiary of Mass. Eye and Ear and affiliate of Harvard Medical School, have found for the first time that a bacterial pathogen can literally mow down protective molecules, known as mucins, on mucus membranes to enter and infect ...

Scott Fordham, president and chief executive officer, announced that Champion Energy Services has partnered with Healthcare Coalition of Texas (HCT), headquartered in Plano, Texas, to offer their members (which represents 62,000 employees and 9,000 medical staff) preferred pricing for residential electricity throughout the state of Texas.

ImmunoCellular Therapeutics today announced that it has entered into an agreement with the University of Pennsylvania under which University of Pennsylvania has granted the Company an exclusive, worldwide license for a patent pending technology for the production of high-activity dendritic cells.

OnCore Manufacturing Services, LLC, a leading provider of electronic manufacturing services (EMS), today announced its intention to enter into a medical product design alliance with Proven Process Medical Devices, Inc.

BioLineRx, a biopharmaceutical development company, announced today it has signed a worldwide, exclusive license agreement with Genoscience and RFS Pharma to develop and commercialize BL-8030, an orally available treatment for Hepatitis C.

MannKind Corporation today announced that it has entered into a purchase agreement with The Mann Group LLC, an entity controlled by MannKind's chief executive officer and principal stockholder, Alfred E. Mann, for the sale of shares of its common stock to The Mann Group.

Impax Pharmaceuticals, the branded products business unit of Impax Laboratories, Inc., announced today that it has licensed from AstraZeneca the exclusive United States (U.S.) commercial rights to Zomig (zolmitriptan) tablet, orally disintegrating tablet, and nasal spray formulations.

Horizon Software International, the leader in K-12 food service technology and online account management, has been awarded a three-year national group purchasing contract with the Premier healthcare alliance.

Columbia University and Health Fidelity, Inc. announced today that they have entered into a license agreement for commercialization of Columbia's MedLEE Natural Language Processing technology.

Shire plc, the global specialty biopharmaceutical company, announced today that it has acquired the rights to develop and market Resolor (prucalopride) in the United States (US) in an agreement with Janssen Pharmaceutica N.V.

Boulder Diagnostics Inc. and the Department of Internal Medicine, Radboud University Nijmegen Medical Centre announced today the entry into a license and collaboration agreement to market the innovative Lyme disease diagnostic test developed at RUNMC.